Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

1 Healthcare Stock Primed for Growth and 2 to Avoid

STE Cover Image

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024. This has weighed on the returns lately as the industry has pulled back by 1.7% over the past six months. This performance is a noticeable divergence from the S&P 500’s 9% return.

Despite the lackluster result, a few diamonds in the rough can produce earnings growth no matter what, and we started StockStory to help you find them. With that said, here is one healthcare stock poised to generate sustainable market-beating returns and two we’re swiping left on.

Two Healthcare Stocks to Sell:

STERIS (STE)

Market Cap: $21.53 billion

Founded in 1985, Steris (NYSE: STE) provides infection prevention, sterilization, and surgical support products for the healthcare, pharmaceutical, and research industries to ensure safety and operational efficiency.

Why Does STE Fall Short?

  1. Adjusted operating margin failed to increase over the last two years, indicating the company made no progress on optimizing its expenses
  2. 1.6 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
  3. Low returns on capital reflect management’s struggle to allocate funds effectively

At $219.34 per share, STERIS trades at 22.4x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than STE.

GoodRx (GDRX)

Market Cap: $1.86 billion

Founded in 2011, GoodRx (NASDAQ: GDRX) provides a platform allowing consumers to compare prescription drug prices, access discounts, and save on medications through its digital tools.

Why Do We Pass on GDRX?

  1. Customer additions have disappointed over the past two years, indicating the company’s value proposition may not be resonating
  2. Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 12.9 percentage points
  3. Negative returns on capital reveal that some of its growth strategies have backfired

GoodRx is trading at $5.17 per share, or 11.8x forward price-to-earnings. If you’re considering GDRX for your portfolio, see our FREE research report to learn more.

One Healthcare Stock to Watch:

Cigna (CI)

Market Cap: $81.41 billion

Serving both corporate clients and individual customers, Cigna (NYSE: CI) offers health insurance and pharmacy benefit management services that cover medical, dental, behavioral health, and vision needs.

Why Could CI Be a Winner?

  1. Market share has increased this cycle as its 17% annual revenue growth over the last two years was exceptional
  2. Enormous revenue base of $247.1 billion gives it power over plan holders and advantageous reimbursement terms with healthcare providers
  3. Earnings growth has comfortably beaten the peer group average over the last five years as its EPS has compounded at 9.9% annually

Cigna’s stock price of $301 implies a valuation ratio of 9.3x forward price-to-earnings. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.

Stocks We Like Even More

With rates dropping, inflation stabilizing, and the elections in the rearview mirror, all signs point to the start of a new bull run - and we’re laser-focused on finding the best stocks for this upcoming cycle.

Put yourself in the driver’s seat by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like United Rentals (+322% five-year return). Find your next big winner with StockStory today for free.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.